121
Participants
Start Date
January 29, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
BL-B01D1
Administration by intravenous infusion
SI-B003
Administration by intravenous infusion
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
Liuzhou People's Hospital, Liuzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Union Hospital Tongji Medical College， Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
NOT_YET_RECRUITING
Hunan Cancer Hospita, Changsha
NOT_YET_RECRUITING
The Second Affiliated Hospital Of Nanchang University, Nanchang
RECRUITING
Linyi Cancer Hospital, Linyi
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an
NOT_YET_RECRUITING
Tianjin Medical University General Hospital, Tianjin
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
INDUSTRY
Sichuan Baili Pharmaceutical Co., Ltd.
INDUSTRY